729 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis

Melinda Gooderham(Queen's University), David Rosmarin(Indiana University School of Medicine), Jonathan Zalevsky(Nektar Therapeutics (United States)), Stephen M. Schleicher(Tennessee Oncology), Trinidad Montero‐Vílchez(Universidad de Granada), Charles Lynde(University of Toronto), Maryam Shayesteh Alam(Barrie Urology Group), Sohail S. Chaudhry(Nektar Therapeutics (United States)), Michael Sticherling(Universitätsklinikum Erlangen), Craig A. Rohan(Wright State University), Pablo Fernández‐Peñas(The University of Sydney), Suzana Ljubojević Hadžavdić(University Hospital Centre Zagreb), Timothy Rodgers(Center for Clinical Research (United States)), Vivian Laquer(Johns Hopkins University), Ansgar Weyergraf, Adam Reich(Rzeszów University of Technology), Mary Tagliaferri(Nektar Therapeutics (United States)), Lucinda M Elko-Simms(Nektar Therapeutics (United States)), Maxwell Sauder(Johns Hopkins University), Adelaide A. Hebert(The University of Texas Health Science Center), Spyridon Gkalpakiotis(Charles University), Neil S. Sadick(Cornell University), Christie Fanton(Nektar Therapeutics (United States)), Wojciech Baran(Wroclaw Medical University), Danni Yu(National Heart Lung and Blood Institute), Zachary Lee(Nektar Therapeutics (United States)), Andreas Wollenberg(University Hospital Augsburg), Yi Liu(Nektar Therapeutics (United States)), Telegdy Eniko(Markusovszky Egyetemi Oktatókórház), Wang Waltz(Nektar Therapeutics (United States)), Jacek C Szepietowski(Wroclaw Medical University), Jenny Gilbert(Nektar Therapeutics (United States)), Michael Sebastian(Mahlo (Germany)), James Q Del Rosso(Dermatology Research Center), Dédée F. Murrell(Sutherland Hospital), William Philip Werschler(University of Washington), Ricardo Tan
British Journal of Dermatology
August 1, 2024
Cited by 2


Related Papers